Published on 21/12/2025
Understanding Insurance Requirements for Clinical Trials in China
Introduction
Insurance is a critical safeguard in clinical trials, ensuring that participants are protected against potential harm and that sponsors fulfill their ethical and legal responsibilities. In China, clinical trial insurance requirements have evolved significantly under the National Medical Products Administration (NMPA) and the 2019 Drug Administration Law. While historically less stringent than in the U.S. or EU, China now mandates clear insurance and indemnity frameworks as part of Good Clinical Practice (GCP) compliance. These requirements cover subject injury compensation, sponsor liability, and site-level obligations, creating a more transparent and participant-focused environment. This article examines the insurance requirements for clinical trials in China, outlining the regulatory framework, challenges, and best practices for sponsors and CROs.
Background and Regulatory Framework
Historic Gaps in Trial Insurance
Prior to reforms, many Chinese clinical trials lacked comprehensive insurance coverage, relying on ad hoc compensation agreements between sponsors and hospitals. This created uncertainty for participants and ethical concerns for regulators and investigators.
NMPA’s Strengthened Requirements
The 2019 Drug Administration Law codified insurance requirements, mandating that all clinical trials must have subject protection mechanisms, either through insurance or sponsor indemnification. Ethics committees now require documented insurance policies before
Case Example: Oncology Trial Insurance Approval
A multinational oncology sponsor submitted a trial protocol without insurance documentation. The local ethics committee delayed approval until the sponsor secured comprehensive liability insurance covering subject injuries. This case highlighted the centrality of insurance in trial approvals.
Core Clinical Trial Insights
Types of Insurance Coverage Required
Sponsors must secure coverage for:
✔️ Medical treatment costs for trial-related injuries
✔️ Disability compensation and death benefits
✔️ Legal liability for sponsor negligence
✔️ Hospital and investigator indemnification
Coverage must be adequate to address trial-specific risks and participant demographics.
Role of Ethics Committees
Ethics committees verify that insurance policies are in place and sufficient. They require details on coverage limits, claims processes, and compensation mechanisms. Without proof of insurance, trials cannot proceed.
Insurance for Multinational Trials
Global sponsors conducting multinational trials must ensure that insurance policies meet both Chinese and global requirements. This often involves dual coverage—local policies for Chinese participants and global insurance for multinational integration.
Challenges for Sponsors and CROs
Key challenges include:
✔️ Variability in insurance premiums across therapeutic areas
✔️ Limited availability of specialized clinical trial insurance products in China
✔️ Complex negotiations between sponsors, CROs, and hospitals
✔️ Lack of clarity on compensation standards for non-serious adverse events
Sponsors must plan insurance early to avoid delays.
Insurance in Investigator Agreements
Clinical trial contracts in China must specify insurance responsibilities. Sponsors typically assume liability for subject injury, while hospitals require indemnification clauses. CROs may coordinate insurance documentation and compliance on behalf of sponsors.
Inspection and Compliance
The NMPA inspects insurance documentation during GCP audits. Findings often include insufficient coverage, unclear claims processes, or expired policies. Non-compliance can delay approvals or result in protocol suspensions.
Best Practices & Preventive Measures
Sponsors should:
✔️ Secure trial-specific liability insurance early in planning
✔️ Ensure coverage includes medical costs, disability, and death compensation
✔️ Provide transparent insurance documentation to ethics committees
✔️ Negotiate clear indemnification clauses with sites
✔️ Engage CROs to manage local insurance procurement and compliance
These measures reduce approval delays and protect participant rights.
Scientific & Regulatory Evidence
China’s insurance requirements reflect ICH E6(R2) GCP and align with WHO and EMA guidelines on subject protection. The 2019 Drug Administration Law formalized insurance obligations, while NMPA GCP inspections emphasize insurance compliance. Comparative analysis shows China’s system is converging with FDA and EMA practices, though local nuances remain.
Special Considerations
High-risk trials, such as oncology, gene therapy, or pediatric studies, may require higher coverage limits. Rare disease trials present unique challenges, as insurance providers may lack actuarial data for compensation models. Sponsors must tailor policies to trial-specific risks and patient populations.
When Sponsors Should Seek Regulatory Advice
Sponsors should seek NMPA advice when planning high-risk or multinational trials involving Chinese participants. Regulatory consultations clarify expectations for coverage levels, acceptable insurance providers, and indemnification standards. Engaging early avoids ethics approval delays.
Case Studies
Case Study 1: Vaccine Trial Insurance Model
A vaccine sponsor collaborated with a Chinese insurer to create a tailored liability policy covering trial-related adverse events. The policy was approved by the ethics committee, enabling rapid trial initiation during a public health emergency.
Case Study 2: Rare Disease Trial Insurance Challenges
A rare disease trial faced difficulties obtaining adequate insurance coverage due to small patient numbers and unknown risks. The sponsor worked with CROs and regulators to design a hybrid model of insurance and sponsor-backed compensation, ensuring patient protection and regulatory compliance.
FAQs
1. Is insurance mandatory for clinical trials in China?
Yes, under the 2019 Drug Administration Law, all clinical trials must have insurance or indemnity mechanisms for subject protection.
2. What does clinical trial insurance cover?
Coverage includes medical costs, disability or death compensation, and legal liability for sponsor negligence or trial-related harm.
3. Who verifies insurance compliance?
Ethics committees review insurance documentation before approving protocols, and the NMPA inspects policies during GCP audits.
4. Are global insurance policies sufficient in China?
No, sponsors must secure local insurance policies for Chinese participants, even if they have global coverage.
5. What challenges exist in securing trial insurance in China?
Challenges include high premiums for risky trials, limited specialized products, and lack of clarity on compensation for minor events.
6. How should sponsors address high-risk trials?
They should negotiate higher coverage limits, engage local insurers early, and supplement policies with sponsor-backed compensation mechanisms.
Conclusion & Call-to-Action
China’s clinical trial insurance requirements have evolved into a transparent and participant-centered framework under NMPA oversight. For sponsors, compliance requires early planning, clear documentation, and robust CRO support. Organizations conducting trials in China must prioritize insurance as a core element of study feasibility and ethics approval, ensuring patient safety and regulatory success. By aligning with local and global standards, sponsors can protect participants while accelerating trial timelines.